Skip to main content

Table 2 HIV infection and ART treatment characteristics, in 2004 and 2014

From: Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort

  2004 2014 p-value
n = 2138 n = 2138  
Time since HIV diagnosis (years), mean (SD) 10.5 (5.5) 20.5 (5.5)* < 0.0001
CD4 count (cells/mm3), median (IQR) 457 (321;634) 647 (479;858) < 0.0001
CD4 count, strata, n (%)    < 0.0001
  ≥ 500 879 (43.6) 1451 (72.0)  
 351–500 546 (27.1) 336 (16.7)  
  < 350 590 (29.3) 228 (11.3)  
Patients with viral suppression (< 50 copies/ml), n (%) 1021 (50.9) 1835 (91.5) < 0.0001
Naïve to ART, n (%) 213 (10.0) 14 (0.7) < 0.0001
Duration of ART (months), mean (SD) 77 (39) 190 (46)* < 0.0001
Current ART drug class, n (%)    < 0.0001
 2 NRTIs + 1 PI/r 505 (23.6) 693 (32.4)  
 2 NRTIs + 1 NNRTI 467 (21.8) 690 (32.3)  
 2 NRTIs + II 0 (0.0) 138 (6.5)  
 Other regimens 751 (35.1) 559 (26.1)  
 No treatment 415 (19.4) 58 (2.7)  
AIDS stage, n (%) 442 (20.7) 525 (24.6)* < 0.0001
  1. Legend: AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, IQR inter-quartile range, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors, NRTI Nucleoside Reverse Transcriptase Inhibitors, PI/r ritonavir-boosted protease inhibitor, SD standard-deviation
  2. *Cumulative data between 2004 and 2014
\